A phase I clinical trial of DARC (360G-Wellcome-099729_Z_12_A)

£271,521

Preclinical development of a novel diagnostic for glaucoma. Glaucoma is the major cause (15 per cent) of irreversible blindness worldwide. A recent UK report suggested 10 per cent earlier detection of glaucoma would save £1billion/year in treatment costs alone.Professor Francesca Cordeiro and colleagues from the Institute of Ophthalmology at University College London, have been given Translation Award support to fund the preclinical development of their Detection of Apoptosing Retinal Cells (DARC) Technology. DARC is a novel technique that utilises the unique optical properties of the eye to allow direct visualisation of dying nerve cells. If successful, early diagnosis and treatment would mean that DARC will increase patient benefit and decrease burden of care costs.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 271521
Applicant Surname Cordeiro
Approval Committee Internal Decision Panel for C&S
Award Date 2016-09-30T00:00:00+00:00
Financial Year 2015/16
Grant Programme: Title Translation Award
Internal ID 099729/Z/12/A
Lead Applicant Prof Francesca Cordeiro
Partnership Value 271521
Planned Dates: End Date 2018-08-31T00:00:00+00:00
Planned Dates: Start Date 2013-06-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Greater London